BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 16361849)

  • 1. Proven strategies to reduce cardiovascular mortality in hemodialysis patients.
    Hampl H; Hennig L; Rosenberger C; Gogoll L; Riedel E; Scherhag A
    Blood Purif; 2006; 24(1):100-6. PubMed ID: 16361849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of optimized heart failure therapy and anemia correction with epoetin beta on left ventricular mass in hemodialysis patients.
    Hampl H; Hennig L; Rosenberger C; Amirkhalily M; Gogoll L; Riedel E; Scherhag A
    Am J Nephrol; 2005; 25(3):211-20. PubMed ID: 15900093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimized heart failure therapy and complete anemia correction on left-ventricular hypertrophy in nondiabetic and diabetic patients undergoing hemodialysis.
    Hampl H; Hennig L; Rosenberger C; Gogoll L; Riedel E; Scherhag A
    Kidney Blood Press Res; 2005; 28(5-6):353-62. PubMed ID: 16534231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemoglobin response and influence on left ventricular hypertrophy after 24-week treatment of a biosimilar epoetin-alfa in hemodialysis patients with anemia.
    Thanakitcharu P; Siriwiwatanakul N
    J Med Assoc Thai; 2007 Dec; 90(12):2574-86. PubMed ID: 18386706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac mortality prevention in uremic patients. Therapeutic strategies with particular attention to complete correction of renal anemia.
    Berweck S; Hennig L; Sternberg C; Dingerkus H; Ludat K; Hampl H
    Clin Nephrol; 2000 Feb; 53(1 Suppl):S80-5. PubMed ID: 10746811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of erythropoietin on cardiovascular prognosis parameters in hemodialysis patients.
    Frank H; Heusser K; Höffken B; Huber P; Schmieder RE; Schobel HP
    Kidney Int; 2004 Aug; 66(2):832-40. PubMed ID: 15253740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal control of blood pressure can reverse left ventricular hypertrophy in uremic hypertensive hemodialysis patients.
    Wu SG; Lin SL; Wu CM; Jeng FR; Su CZ
    Kaohsiung J Med Sci; 1999 Feb; 15(2):62-8. PubMed ID: 10089714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Improvement of left ventricular hypertrophy by anemic-correcting erythropoietin therapy in chronic renal insufficiency].
    Jiang JP; Hou FF; Gao LZ; Pan YB; Yang NS; Chen W; Shu GY; Chen YM; Chen J; Peng WH; Wu JP; Yang ZM
    Zhonghua Nei Ke Za Zhi; 2005 Jan; 44(1):25-9. PubMed ID: 15769393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cardiovascular and hemodynamic effects of erythropoietin in chronic renal failure.
    Singh NP; Chandrashekhar ; Nair M; Anuradha S; Kohli R; Agarwal SK
    J Assoc Physicians India; 2000 Mar; 48(3):301-6. PubMed ID: 11229114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Left ventricular hypertrophy in patient on dialysis].
    Lovcić V; Sebetić D; Klobucić M; Kusec V
    Acta Med Croatica; 2003; 57(1):61-4. PubMed ID: 12876866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD.
    Levin A; Djurdjev O; Thompson C; Barrett B; Ethier J; Carlisle E; Barre P; Magner P; Muirhead N; Tobe S; Tam P; Wadgymar JA; Kappel J; Holland D; Pichette V; Shoker A; Soltys G; Verrelli M; Singer J
    Am J Kidney Dis; 2005 Nov; 46(5):799-811. PubMed ID: 16253719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin <10 g/dL.
    Ayus JC; Go AS; Valderrabano F; Verde E; de Vinuesa SG; Achinger SG; Lorenzo V; Arieff AI; Luño J;
    Kidney Int; 2005 Aug; 68(2):788-95. PubMed ID: 16014057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy.
    Suzuki H; Kanno Y; Kaneko K; Kaneko M; Kotaki S; Mimura T; Takane H
    Ther Apher Dial; 2004 Aug; 8(4):320-7. PubMed ID: 15274684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The long-term behavior and predictors of left ventricular hypertrophy in hemodialysis patients.
    Kutlay S; Dincer I; Sengül S; Nergizoglu G; Duman N; Ertürk S
    Am J Kidney Dis; 2006 Mar; 47(3):485-92. PubMed ID: 16490628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A study of the relationships between angiotensin- converting enzyme gene, chymase gene polymorphisms, pharmacological treatment with ACE inhibitor and regression of left ventricular hypertrophy in essential hypertension patients treated with benazepril.
    He H; Li LM; Cao WH; Sun NL; Liu MZ; Hu YH
    Ann Hum Biol; 2005; 32(1):30-43. PubMed ID: 15788353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regression of left ventricular hypertrophy in hemodialysis patients is possible.
    Hampl H; Sternberg C; Berweck S; Lange D; Lorenz F; Pohle C; Riedel E; Gogoll L; Hennig L
    Clin Nephrol; 2002 Jul; 58 Suppl 1():S73-96. PubMed ID: 12227731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study.
    Ritz E; Laville M; Bilous RW; O'Donoghue D; Scherhag A; Burger U; de Alvaro F;
    Am J Kidney Dis; 2007 Feb; 49(2):194-207. PubMed ID: 17261422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renormalization of high cardiac output and of left ventricular size following long-term recombinant human erythropoietin treatment of anemic dialyzed uremic patients.
    Cannella G; La Canna G; Sandrini M; Gaggiotti M; Nordio G; Movilli E; Maiorca R
    Clin Nephrol; 1990 Dec; 34(6):272-8. PubMed ID: 2073771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Left ventricular (LV) geometry and dipping state are determinants of LV mass reduction with angiotensin-converting enzyme inhibitor antihypertensive treatment.
    Aznaouridis KA; Vyssoulis GP; Karpanou EA; Marinakis AG; Barbetseas JD; Zervoudaki AI; Cokkinos DV; Stefanadis CI
    Blood Press Monit; 2007 Apr; 12(2):87-94. PubMed ID: 17353651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Left ventricular hypertrophy in patients on hemodialysis: importance of anemia].
    Stojimirović B; Petrović D; Obrenović R
    Med Pregl; 2007; 60 Suppl 2():155-9. PubMed ID: 18928184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.